Zydus Lifesciences Ltd Stock Analysis

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Large Cap

BSE Share Price 22-Sep-2023 18:02
595.60 -19.95 (-3.24%)

DeciZen - Make an Informed Decision on Zydus Lifesciences

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Zydus Lifesciences Price Chart

P/E Ratio ( CD) :
Market Cap :
60,286.9 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Zydus Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.

2. Is Zydus Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Zydus Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zydus Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zydus Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zydus Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 14.2%18%25.7%14.8%14%11.8%7.4%12.4%10%8.4%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7,2248,6519,4279,37711,90513,16614,25314,40415,11017,23718,008
YoY Gr. Rt. %-19.8%9%-0.5%27%10.6%8.3%1.1%4.9%14.1%-
Adj EPS 7.711.318.914.417.418.211.922.520.117.425
YoY Gr. Rt. %-46.8%67.9%-23.6%20.6%4.3%-34.5%89.5%-11%-13.5%-
BVPS (₹) 33.641.555.76885.4101.4101.3126.9166173.1184
Adj Net Profit 7851,1531,9361,4781,7821,8591,2172,3072,0541,7562,528
Cash Flow from Ops. 9039941,8941,3129191,2822,9323,2942,1052,689-
Debt/CF from Ops. 32.71.345.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.2%7.7%6.5%14.1%
Adj EPS 9.5%-0.1%13.4%-13.5%
Share Price 15.8% 9.2% 16.6% 67.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 24.63038.923.422.719.411.719.713.710.214
Op. Profit Mgn % 16.620.324.720.323.922.719.623.62120.725.6
Net Profit Mgn % 11.313.720.415.714.714.18.51614.210.414
Debt to Equity
Working Cap Days 1551531581781852132101031071020
Cash Conv. Cycle 66615363801011031018200

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 13.42%

Sales growth is good in last 4 quarters at 21.00%

Return on Equity has declined versus last 3 years average to 14.00%

Sales growth has been subdued in last 3 years 6.54%

Latest Financials - Zydus Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 19.6 25
TTM Sales (₹ Cr.) 9,455 18,008
BVPS (₹.) 142.5 184
Reserves (₹ Cr.) 14,319 18,528
P/BV 4.18 3.24
PE 30.47 23.88
From the Market
52 Week Low / High (₹) 350.30 / 668.50
All Time Low / High (₹) 5.53 / 673.70
Market Cap (₹ Cr.) 60,287
Equity (₹ Cr.) 101.2
Face Value (₹) 1
Industry PE 41.7

Management X-Ray of Zydus Lifesciences :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zydus Lifesciences

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Zydus Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zydus Lifesciences on 22-Sep-2023 18:02 is : 595.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2023 18:02 the market cap of Zydus Lifesciences stood at ₹ 60,286.9.
The latest PE ratio of Zydus Lifesciences as of 22-Sep-2023 18:02 is 30.47.
The latest PB ratio of Zydus Lifesciences as of 22-Sep-2023 18:02 is 4.18
The 52-week high of Zydus Lifesciences is ₹ 668.5 and the 52-week low is ₹ 350.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Zydus Lifesciences is ₹ 9,455 ( Cr.) .

About Zydus Lifesciences Ltd

Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Business verticals / products

  • Human Health Formulations
  • Consumer Wellness
  • Animal Healthcare



  • The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.


  • Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
  • Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.


  • Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.


  • Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.


  • The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.


  • Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.


  • The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
  • The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.


  • It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.


  • Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.


  • The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
  • API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.


  • Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.


  • Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now